This application details the collaborative, leadership role of the Gynecologic Oncology Group (GOG) Statistical and Data Center (SDC) in determining the GOG research agenda and accomplishing its mission of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of Gynecologic malignancies. The SDC is comprised of four Divisions (Biostatistics and Science, Information Technology, Data Management, and Administration) and features unparalleled experience in clinical trials investigating gynecologic malignancies. Its members participate in every aspect of Group activities and are inherently involved in GOG Leadership. Specific responsibilities are governed by comprehensive SOPs and embrace all aspects of Group research, including concept development, study design, protocol conduct, data acquisition and quality control, analysis, and publication of results. This grant period has been highlighted by exciting, innovative advances. The SDC has entered into collaboration with the University at Buffalo, Roswell Park Cancer Institute, and the New York State Center of Excellence. This has provided an academic setting for the SDC, and greatly enhanced its scientific expertise with the infusion of faculty with diverse talents. Technologic advances have revolutionized GOG data management with the development and refinement of electronic data submission and specimen tracking. Management strategies have enhanced productivity and efficiency.
The role of the SDC is highly relevant to research in gynecologic oncology. Its members have the responsibility to ensure that the design of the research is feasible, that the data are of high quality and analyzed appropriately, and ultimately, that the results are interpreted properly and disseminated in a timely fashion. The ability to professionally attain these objectives is essential to high quality research.
|Cosgrove, Casey M; Tritchler, David L; Cohn, David E et al. (2018) An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. Gynecol Oncol 148:174-180|
|Gee, Michael S; Atri, Mostafa; Bandos, Andriy I et al. (2018) Identification of Distant Metastatic Disease in Uterine Cervical and Endometrial Cancers with FDG PET/CT: Analysis from the ACRIN 6671/GOG 0233 Multicenter Trial. Radiology 287:176-184|
|Olawaiye, Alexander B; Java, James J; Krivak, Thomas C et al. (2018) Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 151:18-23|
|Hamilton, C A; Miller, A; Casablanca, Y et al. (2018) Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study. Gynecol Oncol 148:275-280|
|Norquist, Barbara M; Brady, Mark F; Harrell, Maria I et al. (2018) Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clin Cancer Res 24:777-783|
|Chan, John K; Brady, William; Monk, Bradley J et al. (2018) A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). Gynecol Oncol 150:247-252|
|Horowitz, Neil S; Larry Maxwell, G; Miller, Austin et al. (2018) Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. Gynecol Oncol 148:49-55|
|Bishop, Erin A; Java, James J; Moore, Kathleen N et al. (2018) Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study. Am J Obstet Gynecol 218:109.e1-109.e11|
|Valicenti, Richard K; Pugh, Stephanie L; Trabulsi, Edouard J et al. (2018) First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy. Int J Radiat Oncol Biol Phys 100:695-701|
|Aghajanian, Carol; Filiaci, Virginia; Dizon, Don S et al. (2018) A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol 150:274-281|
Showing the most recent 10 out of 484 publications